ASH 2023 | Investigating the non-coding myeloma genome
Mutations that occur within the 98% of the genome which is non-coding are poorly understood. Gareth Morgan, MD, PhD, FRCP, FRCPath, NYU Langone Health, New York City, NY, comments on the use of whole-genome sequencing (WGS) to characterize the non-coding genome and elucidate the mutations in these regions that are crucial in the development and progression of multiple myeloma (MM). Several mutationally enhanced regions (MERs) have been identified upstream of important genes, and further investigation is necessary to understand how this may affect the behavior of cancer cells. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research Funding: Janssen Pharmaceuticals
